



Document details

[Back to results](#) | 1 of 1[Export](#) [Download](#) [Print](#) [E-mail](#) [Save to PDF](#) [Save to list](#) [More...](#)[View at Publisher](#)

Materials Science Forum

Volume 981 MSF, 2020, Pages 247-252

Postgraduate Symposium on Industrial Science and Technology, SISTEC 2019; Kuantan; Malaysia; 22 August 2019 through 23 August 2019; Code 238589

Synthesis, In silico molecular docking modeling and pharmacophore mapping of (E)-3-(4-hydroxy-2,6-dimethoxyphenyl)-1-phenylprop-2-en-1-one as potential new inhibitor of microsomal prostaglandin E₂ synthase-1 (Book Chapter)

Sanphetchaloemchok, P.^a Aluwi, M.F.F.M.^a Rullah, K.^b Wai, L.K.^c [Save all to author list](#)^aFaculty of Industrial Science & Technology, Universiti Malaysia Pahang, Lebuhaya Tun Razak, Kuantan, Gambang, Pahang 26300, Malaysia^bKuliyah of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang 26300, Malaysia^cDrug and Herbal Research Centre, Faculty of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, 50300, Malaysia

Abstract

[View references \(10\)](#)

The discovery of potent anti-inflammatory agents through inhibition of prostaglandin E2 (PGE2) via microsomal prostaglandin E2 synthase-1 (mPGES-1) blocking has been proven to be an important game changer in pharmaceutical industry in recent years. In this study, new chalcone derivative has been successfully synthesized via Claisen-Schmidt condensation reaction. The compound was then docked into mPGES-1 active site to predict anti-inflammatory properties through ligand-enzyme interaction investigation. The data collected from in silico molecular docking simulation and pharmacophore modeling studies provide important insight on the molecular conformation and further shed light towards structural modification of the future novel mPGES-1 inhibitor. © 2020 Trans Tech Publications Ltd, Switzerland.

Author keywords

[Chalcone derivative](#) [Docking](#) [mPGES-1](#) [Pharmacophore](#)

Indexed keywords

Engineering controlled terms:

[Condensation reactions](#) [Lipids](#) [Pharmacodynamics](#)

Engineering uncontrolled terms

[Anti-inflammatory agents](#) [Claisen Schmidt condensation](#) [Microsomal prostaglandin](#)
[Molecular conformation](#) [Molecular docking simulations](#) [Pharmaceutical industry](#)
[Pharmacophore modeling](#) [Structural modifications](#)

Engineering main heading:

[Molecular modeling](#)[Metrics](#) [View all metrics](#) 

PlumX Metrics

Usage, Captures, Mentions, Social Media and Citations beyond Scopus.

Cited by 0 documents

Inform me when this document is cited in Scopus:

[Set citation alert](#)[Set citation feed](#)

Related documents

Molecular characterization, biological activity, and in silico study of 2-(3,4-dimethoxyphenyl)-1-phenylprop-2-en-1-one as a novel selective COX-2 inhibitor

Rullah, K. , Mohd Aluwi, M.F.F. , Yamin, B.M. (2015) *Journal of Molecular Structure*

Inhibition of prostaglandin E2 signaling through the EP1 receptor does not affect prostacyclin production in human endothelial cells

Kaneshiro, T. , Okumura, M. , Maalouf, S. (2009) *Prostaglandins and Other Lipid Mediators*

Inhibition of nitric oxide and prostaglandin E2 production by pyrrolylated-chalcones: Synthesis, biological activity, crystal structure analysis, and molecular docking studies

Mohd Faudzi, S.M. , Abdullah, M.A. , Abdull Manap, M.R. (2020) *Bioorganic Chemistry*

View all related documents based on references

References (10)

[View in search results format >](#)

All [Export](#) [Print](#) [E-mail](#) [Save to PDF](#) [Create bibliography](#)

- 1 Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., Li, Y., (...), Zhao, L.
Inflammatory responses and inflammation-associated diseases in organs ([Open Access](#))

(2018) *Oncotarget*, 9 (6), pp. 7204-7218. Cited 224 times.

<http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=23208&path%5B%5D=73165>
doi: 10.18632/oncotarget.23208

[View at Publisher](#)

- 2 FitzGerald, G.A.
Coxibs and cardiovascular disease

(2004) *New England Journal of Medicine*, 351 (17), pp. 1709-1711. Cited 790 times.
doi: 10.1056/NEJMmp048288

[View at Publisher](#)

- 3 Mitchell, J.A., Warner, T.D.
COX isoforms in the cardiovascular system: Understanding the activities of non-steroidal anti-inflammatory drugs

(2006) *Nature Reviews Drug Discovery*, 5 (1), pp. 75-86. Cited 195 times.
doi: 10.1038/nrd1929

[View at Publisher](#)

- 4 Bishop-Bailey, D., Mitchell, J.A., Warner, T.D.
COX-2 in cardiovascular disease ([Open Access](#))

(2006) *Arteriosclerosis, Thrombosis, and Vascular Biology*, 26 (5), pp. 956-958. Cited 36 times.
doi: 10.1161/01.ATV.0000219672.68024.bc

[View at Publisher](#)

- 5 Majed, B.H., Khalil, R.A.
Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn

(2012) *Pharmacological Reviews*, 64 (3), pp. 540-582. Cited 105 times.
<http://pharmrev.aspetjournals.org/content/64/3/540.full.pdf+html>
doi: 10.1124/pr.111.004770

[View at Publisher](#)

- 6 Escribano-Ferrer, E., Queralt Regué, J., Garcia-Sala, X., Boix Montanés, A., Lamuela-Raventos, R.M.
In vivo anti-inflammatory and antiallergic activity of pure naringenin, naringenin chalcone, and quercetin in Mice

(2019) *Journal of Natural Products*, 82 (2), pp. 177-182. Cited 5 times.
<http://pubs.acs.org/journal/jnprdf>
doi: 10.1021/acs.jnatprod.8b00366

[View at Publisher](#)

- 7 Hosseinzade, A., Sadeghi, O., Biregani, A.N., Soukhtehzari, S., Brandt, G.S., Esmailzadeh, A. Immunomodulatory effects of flavonoids: Possible induction of T CD4+ regulatory cells through suppression of mTOR pathway signaling activity ([Open Access](#))
(2019) *Frontiers in Immunology*, 10 (JAN), art. no. 51. Cited 4 times.
www.frontiersin.org/Immunology
doi: 10.3389/fimmu.2019.00051
- [View at Publisher](#)
-
- 8 Lee, H.-H., Moon, Y., Shin, J.-S., Lee, J.-H., Kim, T.-W., Jang, C., Park, C., (...), Lee, K.-T. A novel mPGES-1 inhibitor alleviates inflammatory responses by downregulating PGE₂ in experimental models
(2019) *Prostaglandins and Other Lipid Mediators*, 144, art. no. 106347. Cited 2 times.
www.elsevier.com/locate/prostaglandins
doi: 10.1016/j.prostaglandins.2019.106347
- [View at Publisher](#)
-

- 9 Rullah, K., Mohd Aluwi, M.F.F., Yamin, B.M., Abdul Bahari, M.N., Wei, L.S., Ahmad, S., Abas, F., (...), Wai, L.K. Inhibition of prostaglandin E₂ production by synthetic minor prenylated chalcones and flavonoids: Synthesis, biological activity, crystal structure, and in silico evaluation
(2014) *Bioorganic and Medicinal Chemistry Letters*, 24 (16), pp. 3826-3834. Cited 25 times.
<http://www.journals.elsevier.com/bioorganic-and-medicinal-chemistry-letters/>
doi: 10.1016/j.bmcl.2014.06.061
- [View at Publisher](#)
-
- 10 Luz, J.G., Antonysamy, S., Kuklish, S.L., Condon, B., Lee, M.R., Allison, D., Yu, X.-P., (...), Fisher, M.J. Crystal Structures of mPGES-1 Inhibitor Complexes Form a Basis for the Rational Design of Potent Analgesic and Anti-Inflammatory Therapeutics
(2015) *Journal of Medicinal Chemistry*, 58 (11), pp. 4727-4737. Cited 35 times.
<http://pubs.acs.org/jmc>
doi: 10.1021/acs.jmedchem.5b00330
- [View at Publisher](#)

✉ Aluwi, M.F.F.M.; Faculty of Industrial Science & Technology, Universiti Malaysia Pahang, Lebuhaya Tun Razak,

Kuantan, Gambang, Pahang, Malaysia; email:fasihi@ump.edu.my

© Copyright 2020 Elsevier B.V., All rights reserved.

[◀ Back to results](#) | 1 of 1

[^ Top of page](#)

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語に切り替える](#)

[切换到简体中文](#)

[切換到繁體中文](#)

[Русский язык](#)

Customer Service

[Help](#)

[Contact us](#)

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.